All Stories

  1. Mortality and kidney outcomes in ANCA-associated vasculitis: determinants from a real-world cohort
  2. Sociodemographic and Clinical Determinants of Colchicine Adherence in Adults with Familial Mediterranean Fever: A Cross-Sectional Study
  3. Efficacy and safety of leflunomide with tumor necrosis factor inhibitors in psoriatic arthritis: a retrospective analysis
  4. Comparison of Systemic Corticosteroid Therapy Practices Between Pediatric and Adult Rheumatologists: A Multicenter Survey Study
  5. Treatment response and retention rates of bDMARDs in advanced spinal ankylosis or bamboo spine: Real-world data from the HUR-BIO registry
  6. Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project
  7. Risk of intestinal involvement in mucocutaneous-onset Behçet’s disease: data from the AIDA network registry
  8. Agreement between large language models, human reviewers, and authors in evaluating STROBE checklists for observational studies in rheumatology
  9. Efficacy, retention, and safety of baricitinib in real-life: HUR-BIO monocentric experience
  10. Evaluation of physiotherapy and rehabilitation awareness of physicians working with rheumatological patients: The example of Türkiye
  11. Building bridges for early-career rheumatologists in Türkiye: insights from the Turkish Society for Rheumatology—Young Rheumatologists
  12. The joint-local renin–angiotensin system in rheumatoid arthritis and osteoarthritis: mechanistic evidence, disease-specific patterns, and translational perspectives
  13. Synthetic data in rheumatology: a systematic literature review
  14. Turkish Society for Rheumatology recommendations for the diagnosis, follow-up and management of giant cell arteritis
  15. Key factors contributing to gender inequity in global rheumatology awards: a global survey analysis
  16. Risk of major organ involvement in Behçet’s patients with mucocutaneous onset: data from the AIDA Network Registry
  17. The Risk of Developing Ocular Involvement Among Behçet’s Disease Patients Presenting with Mucocutaneous Involvement at Disease Onset: Data from the International AIDA Network Behçet’s Disease Registry
  18. Sleep quality and blood pressure variability after anti-TNF-α treatment in axial spondyloarthritis patients: A prospective preliminary study
  19. Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions
  20. Educational and skill development needs of early-career rheumatologists in Türkiye
  21. Central nervous system demyelination associated with biological agents used in the treatment of rheumatologic diseases: a retrospective cohort study
  22. Behçet's disease beyond the criteria: insights from a tertiary centre in Turkey
  23. Measuring what matters! The role of AAV-PRO in patient-centered care for EGPA: insights from the study by Delvino et al.
  24. Current application, possibilities, and challenges of artificial intelligence in the management of rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis
  25. QuantiFERON-TB Gold Plus for screening and monitoring latent tuberculosis infection in spondyloarthritis patients
  26. From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey
  27. Exploring the 'risk': Comments on the FAERS data regarding the safety of JAK inhibitors by Mikaeili et al.
  28. Comments on the article by Goldman et al.
  29. Beyond being a rheumatologist: Environment, climate change, and carbon footprint – We need an action!
  30. ACPA is a main risk factor for CT-proven pulmonary nodule progression in patients with rheumatoid arthritis
  31. Ethical challenges and regulatory pathways for artificial intelligence in rheumatology
  32. Comments and perspectives on the TREAT EARLIER study
  33. Prevalence, incidence and geographic distribution of familial Mediterranean fever in Turkey: a national cohort study
  34. A nationwide study: prevalence of rheumatoid factor and anti- citrullinated peptide positivity and their contribution to rheumatoid arthritis diagnosis
  35. Correction: Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)
  36. Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)
  37. Unveiling Cancer Risk in ANCA-Associated Vasculitis: Result from the Turkish Vasculitis Study  Group (TRVaS)
  38. Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists. Second reply
  39. Craniocervical junction involvement in inflammatory arthritis: a single-center radiologic study
  40. Factors that predict development of chronic kidney disease in patients with rheumatoid arthritis receiving biologic DMARDs and mortality rates
  41. Adapting HUVAC Vasculitis Registry to a Country-wide online registry system: Turkish Vasculitis Study Group Prospective Database, TRVaS
  42. Costovertebral and costotransverse joint involvement in spondyloarthritis
  43. Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists: reply
  44. The predictors of paradoxical reactions, especially psoriasis, to biologic therapy—findings from the TReasure database: a 5-year follow-up study
  45. AI am a rheumatologist: a practical primer to large language models for rheumatologists
  46. Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry
  47. Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?
  48. Comparison of lupus nephritis and non-lupus nephritides in patients with systemic lupus erythematosus
  49. Derivation and validation of adult Still Activity Score (SAS)
  50. Comparison of demographic, clinic and radiological features of patients with axial spondyloarthritis accompanying familial Mediterranean fever to patients with each condition alone
  51. Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure database
  52. Autoinflammation in psoriatic arthritis: time to better define the multifaceted enemy
  53. Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis
  54. Predicting the response to bDMARD treatment in RA: Then what?
  55. Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience
  56. Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study
  57. Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results
  58. Extremely high erythrocyte sedimentation rate revisited in rheumatic diseases: a singlecenter experience
  59. Can we predict transition from psoriasis to psoriatic arthritis?
  60. The influence of obesity on biological agents treatment response in psoriatic arthritis: HUR-BIO real life results
  61. From asymptomatic to critical illness: decoding various clinical stages of COVID-19
  62. Conventional Synthetic Dmards in Psoriatic Arthritis: Changing Practice in Biologic Era; Real-Life Results from HURBIO-PsA Registry
  63. The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?
  64. Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data
  65. Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data
  66. The frequency of Achilles and plantar calcaneal spurs in gout patients
  67. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
  68. c-ANCA positivity in a patient with relapsing polychondritis: Co-incidence or not? A case and review of the literature
  69. In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?
  70. Iliac artery aneurysm in Behçet’s syndrome: collaborative management is essential
  71. Journey of Vasculitis at Hacettepe University: from the Establishment of University to the Hacettepe AAV Workshop, 2020
  72. Successful treatment of penile Mondor’s disease with infliximab in a patient with Behçet’s disease
  73. Association of disease characteristics with the temporal sequence of skin and musculoskeletal disease onset in psoriatic arthritis
  74. Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience
  75. PILE: a candidate prognostic score in cancer patients treated with immunotherapy
  76. Proposal of a new nomenclature for the underlying pathogenetic mechanism of severe Coronavirus Disease-19: “Inflammatory Thrombosis with Immune Endotheliitis—ITIE”
  77. Mediastinal mass in a patient with rheumatoid arthritis: lymphoid cystic thymic hyperplasia
  78. Clinical Characteristics and Outcome of ANCA-Associated Vasculitis; Experience of A Single Reference Vasculitis Center
  79. Spinal and cerebral hematoma in systemic lupus erythematosus and antiphospholipid syndrome: is drug interaction the culprit?
  80. Treatment modalities in psoriatic arthritis
  81. Geoepidemiology and clinical characteristics of neonatal lupus erythematosus: a systematic literature review of individual patients’ data
  82. Temporomandibular disorders in ankylosing spondylitis: a cross-sectional, monocentric study
  83. Histopathological subgrouping versus renal risk score for the prediction of end-stage renal disease in ANCA-associated vasculitis
  84. Comparison of Diagnostic Subgroup Survivals of Patients Who Admitted for Fever of Unknown Etiology Evaluation: Long-term Results of Single-centre, Prospective Study
  85. Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)
  86. Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia
  87. Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial
  88. Correction to: Proposal for a simple algorithm to differentiate adult-onset Still’s disease with other fever of unknown origin causes: a longitudinal prospective study
  89. Proposal for a simple algorithm to differentiate adult-onset Still’s disease with other fever of unknown origin causes: a longitudinal prospective study
  90. Some concerns from Turkey
  91. Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature
  92. Blood group ‘A’ may have a possible modifier effect on familial Mediterranean fever and blood group ‘0’ may be associated with colchicine resistance
  93. Aspergillus Pneumonia in a Patient With Adult-Onset Still Disease Successfully Treated With Anakinra
  94. Familial Mediterranean fever: New insights into cancer immunoprevention?
  95. Increased psoriasis frequency in patients with familial Mediterranean fever
  96. The association of various social capital indicators and physical activity participation among Turkish adolescents
  97. Poor outcomes among elderly patients hospitalized for influenza-like illness
  98. Increased cancer risk in patients with periodontitis
  99. Comparing polyarteritis nodosa in children and adults: a single center study
  100. Amniotic Membrane Transplantation for Spontaneous Corneal Perforation in a Case Of Rheumatoid Arthritis
  101. Behçet Disease With Vascular Involvement